.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tradr 2X Short TSLA Daily ETF
TSLQ
5
ProShares UltraPro Short S&P500 ETF
SPXU
US Stock MarketDetailed Quotes
CRBP Corbus Pharmaceuticals
- 7.200
- -0.300-4.00%
Close Apr 29 16:00 ET
88.07MMarket Cap-1.96P/E (TTM)
7.400High7.000Low123.16KVolume7.400Open7.500Pre Close882.34KTurnover1.64%Turnover RatioLossP/E (Static)12.23MShares61.90052wk High0.62P/B54.19MFloat Cap4.64052wk Low--Dividend TTM7.53MShs Float323.400Historical High--Div YieldTTM5.33%Amplitude2.110Historical Low7.163Avg Price1Lot Size
Corbus Pharmaceuticals Stock Forum
Sign in to post a comment
$Corbus Pharmaceuticals (CRBP.US)$
Next-Gen Obesity Drug Shows 50x Better Safety Profile Than Previous Treatments as Clinical Trials Begin
Next-Gen Obesity Drug Shows 50x Better Safety Profile Than Previous Treatments as Clinical Trials Begin
1
$Corbus Pharmaceuticals (CRBP.US)$
The Phase 1 clinical trial results for CRB-701 represent a significant advancement in the antibody-drug conjugate (ADC) space, particularly in addressing the historical challenges of ADC toxicity profiles. The observed 4% combined rate of peripheral neuropathy across both Western and Chinese studies is notably lower than existing ADC treatments, where rates can exceed 30-50% with current standard-of-care options.
The drug's differentiat...
The Phase 1 clinical trial results for CRB-701 represent a significant advancement in the antibody-drug conjugate (ADC) space, particularly in addressing the historical challenges of ADC toxicity profiles. The observed 4% combined rate of peripheral neuropathy across both Western and Chinese studies is notably lower than existing ADC treatments, where rates can exceed 30-50% with current standard-of-care options.
The drug's differentiat...
2
1
$Corbus Pharmaceuticals (CRBP.US)$
Breakthrough Cancer Drug CRB-701 Delivers Powerful Results in Phase 1 Trial: Multiple Tumor Types Respond
Breakthrough Cancer Drug CRB-701 Delivers Powerful Results in Phase 1 Trial: Multiple Tumor Types Respond
$Corbus Pharmaceuticals (CRBP.US)$
Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets
Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets
1
$Corbus Pharmaceuticals (CRBP.US)$ wtf bought at 18.50 and now 14.9 🥲🥹🙏
$Corbus Pharmaceuticals (CRBP.US)$
wow drop 62%. 😲
wow drop 62%. 😲
1
1
Got in at $16, this is gonna be a pretty long hold for me, wanna see how it plays out
5
3
No comment yet
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
J L 7 2 : This stock is currently lifeless, and even the best news cannot attract stock enthusiasts to join in the fun.